세계의 디프테리아, 파상풍, 백일해 혼합백신 시장 규모 : 제품 유형별, 연령층별, 최종사용자별, 지역 범위별 및 예측

Global Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market Size By Product Type, By Age Group, By End-User, By Geographic Scope And Forecast

US $ 3,950 ￦ 5,493,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 보고서의 다운로드와 인쇄가 가능합니다.

US $ 4,850 ￦ 6,745,000

PDF & Excel (5 User License)

PDF 및 Excel 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 보고서의 다운로드와 인쇄가 가능합니다.

US $ 7,550 ￦ 10,500,000

PDF & Excel (Enterprise User License)

PDF 및 Excel 보고서를 동일기업내 모든 분들이 이용할 수 있는 라이선스입니다. 보고서의 다운로드와 인쇄가 가능합니다.

한글목차

디프테리아, 파상풍, 백일해 혼합백신 시장 규모 추이 및 예측

디프테리아, 파상풍, 백일해 혼합백신 시장 규모는 2024년 55억 46만 달러로 평가되었고, 2026-2032년 연평균 5.17% 성장하여 2032년에는 82억 3,255만 달러에 달할 것으로 예측됩니다.

• DTaP 백신은 디프테리아균과 파상풍균의 불활성화 독소 또는 성분과 백일해균의 항원을 포함하는 혼합백신입니다. 보통 소아기 정기 예방접종의 일환으로 영유아에게 접종합니다. 이 백신은 신체의 면역 체계를 자극하여 이러한 세균성 병원체에 대한 항체를 생성하여 이러한 병원체가 유발하는 질병에 대한 면역 및 방어력을 제공합니다.
• 디프테리아는 심각한 호흡기 증상과 생명을 위협하는 합병증을 유발할 수 있는 세균성 감염 질환으로, DTaP 백신은 디프테리아균이 생산하는 독소를 중화시키는 항체를 생성하도록 면역체계를 자극하여 디프테리아를 예방합니다.
• 파상풍은 신경계를 침범해 근육의 경직과 경련을 일으키는 세균성 감염 질환으로, DTaP 백신에는 파상풍 원인균인 클로스트리듐 테타니가 생산하는 독소에 대한 면역을 유도하는 성분이 포함되어 있습니다.
• 백일해는 심한 기침 발작이 특징인 전염성 호흡기 질환으로, 백일해 백신에는 백일해균 항원이 포함되어 있어 백일해 감염으로부터 자신을 보호할 수 있는 항체 생성을 자극합니다.
• 현재 진행 중인 연구는 효능, 안전성, 방어기간을 개선한 DTaP 백신의 개량형 제제 개발을 목표로 하고 있습니다. 여기에는 면역 반응을 최적화하고 부작용을 줄이기 위한 새로운 보조제, 전달 시스템, 항원 조합의 개발이 포함됩니다.

디프테리아-파상풍-백일해 혼합백신 시장 역학

세계 디프테리아-파상풍-백일해 혼합백신 시장을 형성하는 주요 시장 역학은 다음과 같습니다.

주요 시장 성장 촉진요인

• 예방접종에 대한 인식 증가: 디프테리아, 파상풍, 백일해와 같은 질병 예방에 있어 예방접종의 중요성에 대한 보호자, 간병인, 의료진의 인식이 높아지면서 교육 캠페인과 공중보건 이니셔티브에 힘입어 DTaP 백신에 대한 수요가 급증하고 있으며, 이는 시장 확대로 이어지고 있습니다. 시장 확대로 이어졌습니다.
• 백일해 발생률 증가: 백일해 유행은 복잡한 질병 전파 및 집단 면역을 달성하는 데 있어서의 도전의 결과입니다. 백일해 유행의 원인으로는 면역력 저하, 불완전한 백신 접종률, 백일해균의 진화 등을 들 수 있습니다. 진단이 어렵기 때문에 치료가 늦어지고 감염 위험이 높아집니다. 백일해 환자 증가는 시장 성장을 가능하게 합니다.
• 의료비 지출 증가: 신흥국의 의료비 지출 증가는 예방책, 특히 백신 접종 프로그램에 대한 투자를 촉진하고 있습니다. 의료 서비스 제공업체들은 정부 기관 및 국제기구와의 파트너십을 통해 특히 의료 서비스가 취약한 오지 지역에서의 백신 접종 및 보급을 확대하기 위해 노력하고 있습니다. 예방 의료 대책, 특히 백신 접종 프로그램에 대한 이러한 노력 증가는 시장 성장을 가속하고 있습니다.
• 백신 제형의 발전: 혁신적인 제형 전략, 보조제, 항원 제시 시스템, 전달 메커니즘의 강화로 DTaP 백신의 성능이 향상되고, 안정성, 보존 기간, 투여 편의성이 개선되어 시장 확대가 촉진되고 있습니다.

주요 과제

• 백신 공급 부족: 장비 고장, 품질 관리 문제 등 제조상의 혼란은 DTaP 백신의 생산을 방해하여 백신 공급 부족으로 이어질 수 있습니다. 운송 지연, 보관 문제 등 공급망의 혼란은 공급 부족을 악화시키고, 의료 시설 및 백신 접종 시설에 적시에 유통을 방해하여 혼합백신의 제조 및 공급에 지장을 초래할 수 있습니다.
• 콜드체인 관리의 과제: 콜드체인 관리는 백신의 효능에 매우 중요하지만, 온도 변동은 효능을 저해할 수 있습니다. 전기, 냉장, 운송 인프라에 대한 접근이 제한된 원격지에서는 콜드체인 관리의 또 다른 문제에 직면하게 됩니다. 적절한 취급 프로토콜의 부족은 디프테리아, 파상풍, 백일해 혼합백신 시장을 더욱 제한하고 있습니다.
• 비용에 대한 우려: 디프테리아, 파상풍, 급성 백일해 혼합백신은 자원의 제약, 가용성 제한, 물류 장애, 가격 문제 등으로 인해 중저소득 국가에서는 접종이 어려운 실정입니다. 이는 백신 접종을 방해하고 예방접종률의 격차를 확대할 수 있습니다. 의료시설은 안정적인 재고를 유지하는 데 어려움을 겪고 있으며, 특히 취약 계층의 어린이들이 예방접종 기회를 놓치고 있습니다. 특히 외딴 지역이나 서비스 취약 지역에서의 유통 물류는 혼합백신 시장의 성장을 저해할 수 있습니다.

주요 동향

• 백신 제형 개선: DTaP 백신은 제형, 안전성, 예방 기간을 개선하기 위해 지속적인 연구가 진행되고 있습니다. 여기에는 면역반응을 최적화하고 부작용을 최소화하기 위한 새로운 보조제, 전달 메커니즘, 항원 조합에 대한 연구가 포함되어 시장 성장의 기회를 창출하고 있습니다.
• 연구개발: 연구에서는 효능, 안전성, 접근성을 향상시키기 위해 DTaP 백신 기술이 발전하고 있습니다. 그 중 하나는 mRNA 백신 기술로, 합성 mRNA 분자를 사용하여 특정 항원을 생산하고 강력한 면역반응을 유발하는 기술입니다. 이 접근법은 빠른 개발, 확장성, 면역원성 향상을 가져옵니다. 바이러스 유사 입자, 리포좀, 나노입자 캐리어와 같은 새로운 항원 전달 플랫폼도 연구되고 있습니다.
• 혼합백신: DTaP 백신과 같은 혼합백신의 개발은 단일 제형으로 더 광범위한 감염에 대한 방어력을 제공할 수 있기 때문에 관심이 높아지고 있습니다.

목차

제1장 세계의 DTaP 혼합백신 시장 서론

• 시장 개요
• 조사 범위
• 전제조건

제2장 주요 요약

제3장 VERIFIED MARKET RESEARCH의 조사 방법

• 데이터 마이닝
• 밸리데이션
• 1차 자료
• 데이터 소스 리스트

제4장 세계의 DTaP 혼합백신 시장 전망

• 개요
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
• Porter's Five Forces 모델
• 밸류체인 분석

제5장 세계의 DTaP 혼합백신 시장 : 제품 유형별

• 개요
• DTaP
• TD
• Tdap

제6장 세계의 DTaP 혼합백신 시장 : 연령층별

• 개요
• 성인
• 소아

제7장 세계의 DTaP 혼합백신 시장 : 최종사용자별

• 개요
• 병원
• 진료소
• 백신접종센터

제8장 세계의 DTaP 혼합백신 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 기타 유럽
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 기타 아시아태평양
• 세계 기타 지역
  • 라틴아메리카
  • 중동 및 아프리카

제9장 세계의 DTaP 혼합백신 시장 경쟁 구도

• 개요
• 기업의 시장 순위
• 주요 개발 전략

제10장 기업 개요

• Bionet-Asia
• Johnson & Johnson
• GlaxoSmithKline plc
• Mass biologics
• Meiji Holdings Co., Ltd.
• Merck & Co., Inc.
• Panacea Biotech Ltd.
• Sanofi
• Serum Institute of India Pvt. Ltd.
• namely AJ Vaccines

제11장 기업 개요 부록

• 관련 조사

LSH

영문 목차

영문목차

Diphtheria, Tetanus And Acellular Pertussis Combined Vaccine Market Size And Forecast

Diphtheria, Tetanus And Acellular Pertussis Combined Vaccine Market size was valued at USD 5500.46 Million in 2024 and is projected to reach USD 8232.55 Million by 2032, growing at a CAGR of 5.17% from 2026 to 2032.

• The DTaP vaccine is a combination vaccine that contains inactivated toxins or components of the diphtheria and tetanus bacteria, as well as antigens from the Bordetella pertussis bacterium. It is administered through a series of shots typically given to infants and young children as part of routine childhood immunization schedules. The vaccine stimulates the body's immune system to produce antibodies against these bacterial pathogens, providing immunity and protection against the diseases they cause.
• Diphtheria is a bacterial infection that can cause severe respiratory symptoms and potentially life-threatening complications. The DTaP vaccine helps prevent diphtheria by stimulating the immune system to produce antibodies that neutralize the toxins produced by the bacterium Corynebacterium diphtheriae.
• Tetanus is a bacterial infection that affects the nervous system, leading to muscle stiffness and spasms. The DTaP vaccine includes a component that induces immunity against the toxin produced by the bacterium Clostridium tetani, which causes tetanus.
• Pertussis is a highly contagious respiratory infection characterized by severe coughing fits. The DTaP vaccine contains antigens from Bordetella pertussis, which stimulate the production of antibodies to protect against pertussis infection.
• Ongoing research aims to develop improved formulations of the DTaP vaccine with enhanced efficacy, safety, and duration of protection. This includes the development of newer adjuvants, delivery systems, and antigen combinations to optimize immune responses and reduce side effects.

Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market Dynamics

The key market dynamics that are shaping the global diphtheria, tetanus, and acellular pertussis combined vaccine market include:

Key Market Drivers:

• Growing Awareness about Vaccination: The growing awareness of the importance of vaccination in preventing diseases like diphtheria, tetanus, and pertussis among parents, caregivers, and healthcare practitioners has led to a surge in demand for DTaP vaccines, fueled by educational campaigns and public health initiatives, resulting in market expansion.
• Increasing Incidence of Pertussis: Pertussis outbreaks are a result of complex disease transmission and challenges in achieving herd immunity. Factors include waning immunity, incomplete vaccination coverage, and the evolution of Bordetella pertussis. Diagnosis is difficult, leading to treatment delays and increased risk of transmission. Rising cases of pertussis enable market growth.
• Growing Healthcare Expenditure: The rise in healthcare expenditure in developing economies is driving investments in preventive measures, particularly vaccination programs. Healthcare providers, through partnerships with government agencies and international organizations, ensure widespread vaccine access and distribution, especially in underserved and remote areas. This growing commitment to preventive healthcare measures, particularly vaccination programs, is boosting market growth.
• Growing advancements in vaccine formulations: Research is enhancing DTaP vaccine performance through innovative formulation strategies, enhancing adjuvants, antigen presentation systems, and delivery mechanisms, leading to improved stability, shelf-life, and administration ease, thereby promoting market expansion.

Key Challenges:

• Vaccine Supply Shortages: Manufacturing disruptions, such as equipment malfunctions or quality control issues, can impede the production of DTaP vaccines, leading to inadequate supply levels. Supply chain disruptions, like transportation delays or storage issues, can exacerbate shortages and hinder timely distribution to healthcare facilities and vaccination sites, thereby challenging the manufacturing and supply of the combined vaccine.
• Cold Chain Management Challenges: Cold chain management is crucial for vaccine efficacy, but temperature fluctuations can compromise effectiveness. Remote areas with limited access to electricity, refrigeration, and transportation infrastructure face additional challenges in cold chain management. Lack of proper handling protocols further restricts the combined diphtheria, tetanus, and acellular pertussis vaccine market.
• Concerns Regarding Costing: DTaP vaccines are challenging to access in low- and middle-income countries due to resource constraints, limited availability, logistical hurdles, and affordability issues. This can impede vaccination efforts and increase immunization coverage disparities. Healthcare facilities struggle to maintain consistent stocks, leading to missed vaccination opportunities, especially for vulnerable children. Distribution logistics, particularly in remote or underserved areas, may hinder the combined vaccine market growth.

Key Trends:

• Improved Vaccine Formulations: The DTaP vaccine is under continuous research to improve its formulations, safety, and protection duration. This involves exploring novel adjuvants, delivery mechanisms, and antigen combinations to optimize immune responses and minimize side effects, creating market growth opportunities.
• Research and Development: Research is advancing DTaP vaccine technology to improve efficacy, safety, and accessibility. One innovation is mRNA vaccine technology, which uses synthetic mRNA molecules to produce specific antigens, triggering robust immune responses. This approach offers rapid development, scalability, and enhanced immunogenicity. Novel antigen delivery platforms like virus-like particles, liposomes, and nanoparticle carriers are also being explored.
• Combination Vaccines: The development of combination vaccines, such as the DTaP vaccine, is gaining interest due to its potential to offer protection against a wider range of infectious diseases in a single formulation.

Global Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market Regional Analysis

Here is a more detailed regional analysis of the global diphtheria, tetanus, and acellular pertussis combined vaccine market:

North America:

• North America is poised to maintain a substantial stake in the DTaP combined vaccine market, propelled by its robust healthcare infrastructure, elevated vaccination rates, and comprehensive government-driven immunization campaigns.
• The region benefits from cutting-edge technological advancements, fortified by stringent regulatory frameworks, which collectively bolster the market's growth trajectory.
• Moreover, heightened disease awareness among both healthcare professionals and the general populace further amplifies the demand for DTaP vaccines in North America.
• This comprehensive ecosystem fosters a conducive environment for the continued expansion of the DTaP Combined Vaccine Market, ensuring widespread accessibility and efficacy of preventive healthcare measures against diphtheria, tetanus, and pertussis throughout the region.

Europe:

• Europe stands out as a significant market for DTaP vaccines, distinguished by its well-established vaccination policies, comprehensive immunization coverage, and proactive approaches to disease prevention.
• Europe's commitment to research and development (R&D) fosters innovation in vaccine technology and formulation. Increasing investments in R&D initiatives, alongside collaborations between public health agencies, academic institutions, and vaccine manufacturers, drive advancements in DTaP vaccine development.
• Europe's proactive disease prevention strategies focus on early detection, surveillance, and response to infectious diseases, including those preventable by vaccination.
• Strong partnerships between public health authorities and healthcare providers enhance disease surveillance efforts, enabling timely interventions to control disease outbreaks and minimize their impact on public health.

Asia Pacific:

• Rapid urbanization and population growth in countries like China, India, and Japan further contribute to the expansion of the DTaP Combined Vaccine Market. As urban populations increase, so does the demand for healthcare services, including immunization.
• Governments in these countries are implementing initiatives to strengthen healthcare infrastructure and improve access to healthcare services in both urban and rural areas, thereby facilitating the expansion of immunization programs.
• Additionally, government initiatives aimed at enhancing healthcare infrastructure play a crucial role in driving market expansion.
• Investments in healthcare facilities, vaccination clinics, and cold chain logistics contribute to the efficient delivery and distribution of DTaP vaccines, ensuring that they reach remote and underserved areas.

Global Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market: Segmentation Analysis

The Global Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market is segmented based on Product Type, Age Group, End User, And Geography.

Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market, By Product Type

• DTaP Vaccines
• TD Vaccines
• Tdap Vaccines

Based on Product Type, the market is categorized into DTaP, TD, and Tdap. The DTaP segment dominated the global DTP vaccine market. The demand for DTaP and pertussis vaccines is driving global growth. WHO states immunization can prevent 3.5-5 million deaths annually. Since vaccines were introduced, few respiratory diphtheria cases have been reported by the CDC. Unvaccinated travelers face high infection risks, so governments mandate immunization for travelers visiting countries with infectious diseases. According to WHO In 2022, Coverage of a third dose of a vaccine protecting against diphtheria, tetanus, and pertussis (DTP3) recovered from 81% in 2021 to 84% in 2022. High birth rates, government initiatives, and insurance drive the DTaP vaccine market growth.

Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market, By Age Group

• Adult Vaccines
• Pediatric Vaccines

Based on Age Group, the DTP vaccines market is segmented into Pediatric Vaccines and Adult Vaccines. By age group, the market for vaccines for adults is expected to experience significant growth due to the increase in infectious diseases among adults. Moreover, the segment is likely to see an upsurge in growth due to advancements in research and development and a strong product pipeline during the forecast period. However, the pediatric segment currently dominates the market due to the high demand for DTP vaccines among infants. The pediatrics vaccines segment's potential size is based on the fact that the global birth rate is increasing, boosting the demand for pediatric vaccines.

Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market, By End-User

• Hospitals
• Clinics
• Vaccination Centre

Based on End-User, the market is fragmented into Hospitals, Clinics, and Vaccination Centre. The hospital segment dominated the largest market share throughout the forecast period. Hospitals play a pivotal role as primary healthcare providers, offering a wide array of medical services, including immunization. As key end-users of DTaP vaccines, hospitals serve as vital hubs for administering preventive healthcare measures to individuals across all age groups, from newborns to adults. Their significance lies in their ability to provide comprehensive vaccination services, encompassing routine immunizations as well as rapid responses to disease outbreaks.

Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Diphtheria, Tetanus, And Acellular Pertussis Combined Vaccine is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America accounted for the largest market share of Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccines. Well-established healthcare infrastructure, high vaccination rates, and robust immunization programs contribute to the dominance of the DTP vaccine market. Moreover, ongoing advancements in medical technology and strong regulatory frameworks further bolster market growth in this region.

Key Players

• The "Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Johnson & Johnson, namely AJ Vaccines, and GlaxoSmithKline plc. Merck & Co. Inc., Sanofi, Bionet-Asia, Mass biologics, Meiji Holdings Co., Ltd., Panacea Biotech Ltd., and Serum Institute of India Pvt. Ltd. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market Recent Developments
• In October 2022, the FDA approved Boostrix for pregnant women in their third trimester to prevent pertussis in infants under 2 months old.
• In June 2021, Merck and Sanofi's VAXELIS, the first and only six-in-one pediatric combination vaccine, is now available in the U.S. The vaccine is approved for use in children aged 6 weeks to 4 years to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL DTaP COMBINED VACCINE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL DTaP COMBINED VACCINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL DTaP COMBINED VACCINE MARKET, BY PRODUCT TYPE

• 5.1 Overview
• 5.2 DTaP
• 5.3 TD
• 5.4 Tdap

6 GLOBAL DTaP COMBINED VACCINE MARKET, BY AGE GROUP

• 6.1 Overview
• 6.2 Adult
• 6.3 Pediatric

7 GLOBAL DTaP COMBINED VACCINE MARKET, BY END USER

• 7.1 Overview
• 7.2 Hospitals
• 7.3 Clinics
• 7.4 Vaccination Centers

8 GLOBAL DTaP COMBINED VACCINE MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL DTaP COMBINED VACCINE MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Bionet-Asia
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Johnson & Johnson
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 GlaxoSmithKline plc
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Mass biologics
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Meiji Holdings Co., Ltd.
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Merck & Co., Inc.
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Panacea Biotech Ltd.
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Sanofi
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Serum Institute of India Pvt. Ltd.
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 namely AJ Vaccines
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Research

관련자료